Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://fraserhxyy836271.losblogos.com/41429638/this-new-drug-retatrutide-australia-a-potential-hope-for-losing-weight